secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001193125-23-209020
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd reports Q2 net loss $50.2M; plans pivotal VYD222 trial for COVID-19 prevention
--------------------------------------------------------------------------------

- Net loss of $50.2M ($0.46 per share) vs. $51.0M ($0.47) in Q2 2022; revenue none.
- Cash & equivalents $298.4M; runway into Q4 2024, excluding potential product revenue.
- Plans to initiate CANOPY pivotal trial of VYD222 (~750 participants) using Day 28 neutralizing titers as surrogate endpoint for EUA.
- Phase 1 data showed favorable safety and robust neutralizing titers against Omicron XBB.1.5 at all three doses tested.
- FDA alignment on immunobridging approach for EUA; expects initial CANOPY data by end of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312523209020/0001193125-23-209020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312523209020/d480890d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-209020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer